Leptin-enhanced neointimal hyperplasia is reduced by mTOR and PI3K inhibitors.

@article{Shan2008LeptinenhancedNH,
  title={Leptin-enhanced neointimal hyperplasia is reduced by mTOR and PI3K inhibitors.},
  author={Jian Cheng Shan and Thomas B V Nguyen and Hana Totary-Jain and Hayes M. Dansky and Steven O. Marx and Andrew Robert Marks},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={2008},
  volume={105 48},
  pages={19006-11}
}
Despite the use of the sirolimus (rapamycin) drug-eluting coronary stent, diabetics are at increased risk of developing in-stent restenosis for unclear reasons. Hyperleptinemia, which often coexists with diabetes and metabolic syndrome, is an independent risk factor for progression of coronary artery disease. It has not been determined whether elevated circulating leptin decreases the efficacy of the sirolimus drug-eluting stent in inhibiting neointimal hyperplasia, the process underlying… CONTINUE READING